AbbVie forecasts 2026 adjusted EPS of $13.87-$14.07 as it expects ~$67.6B revenue and Q3 EPS of $3.84-$3.88 (NYSE:ABBV)

AbbVie provided forward guidance for 2026 with adjusted EPS targeting $13.87–$14.07 and expected revenue of approximately $67.6 billion, representing a measured growth trajectory. The company's Q3 EPS forecast of $3.84–$3.88 suggests sequential stability in near-term profitability, though the range reflects inherent execution uncertainty in the pharmaceutical cycle.

The guidance emphasizes momentum in key franchises, particularly Skyrizi (psoriasis/dermatology) and Rinvoq (rheumatology), which are driving incremental revenue contribution. Neuroscience catalysts are positioned as potential upside drivers longer-term, signaling management confidence in pipeline progression. However, the Apogee deal dilution caveat—likely referring to the acquisition's impact on near-term earnings accretion—tempers the bullish narrative and suggests near-term margin compression from integration costs.

The guidance range widens modestly year-over-year, reflecting both opportunity and risk in execution. AbbVie's ability to offset Apogee dilution through organic franchise growth and pipeline advancement will be critical to shareholder returns. The neutral sentiment reflects balanced guidance: no material negative surprise, but also limited upside surprise priced in.

Sector implication: This guidance is consistent with large-cap pharma stability expectations. The Health Care sector often benefits from defensive positioning in uncertain macro environments, though AbbVie's growth-dependent outlook (Skyrizi, neuroscience) ties it moderately to risk-on sentiment rather than pure defensive rotation.